Exploring the environmental impact of medicines: findings from an exploratory project by NICE’s HTA Lab

Pharma's Eco Footprint

The environmental toll of pharmaceuticals has surged into focus amid broader climate imperatives. Production alone accounts for 96% of the sector's carbon footprint, driven by energy-intensive synthesis of active ingredients. Recent data pegs the industry at 3% of global greenhouse gases, higher than car manufacturing. Pollution from residues enters waterways via manufacturing effluent and patient excretion, persisting due to drugs' designed stability.

Key developments include the WHO's 2024 guidance on curbing antibiotic manufacturing waste, which addresses antimicrobial resistance amplified by environmental releases. In Europe, proposed EU rules demand recyclable packaging by 2030, with exemptions for medicine contact materials until 2035. The US EPA updated hazardous waste pharma rules in 2019, but state-level adoptions vary, with Minnesota requiring PFAS disclosures from July 2026 and bans by 2032. These measures respond to findings like diclofenac-linked vulture extinctions in Asia and endocrine disruptions in fish populations.

Impacts ripple widely. Aquatic toxicity affects food chains, with studies showing behavioral changes in wildlife that jeopardize species survival. Human exposure via contaminated water and food heightens risks, though quantified effects remain understudied. Economically, remediation burdens taxpayers; for instance, upgrading wastewater treatment to remove pharma traces could cost European utilities €1 billion yearly. Stakeholders like farmers face crop contamination, while healthcare systems grapple with sustainability mandates.

Tensions arise in balancing eco-factors with clinical needs. NICE's HTA Lab project, launched in 2023, probes comparing impacts for similar-efficacy drugs, but pharma groups resist broad regs like Minnesota's, citing unworkable deadlines and federal conflicts. Non-obvious trade-offs include potential innovation stifling—greener synthesis might raise costs 10-20% initially—or favoring new drugs over generics lacking environmental data. Counterarguments note that inaction exacerbates biodiversity loss, with 2025 reports linking pharma pollution to 14% of AMR cases globally.